Aegros Ltd

Safe, secure, sustainable supply of therapeutic plasma products

Trade Now

Safe, secure, sustainable supply of therapeutic plasma products



Health Tech





Investment Highlights

  • The Future of Plasma Fractionation Has Arrived - Aegros HaemaFrac®

  • This innovative technology reduces production steps, eliminates the need for solvents, and utilizes electrical charge to isolate plasma proteins with high yield, purity, and activity, offering cost savings, environmental benefits, improved safety, and enhanced protection against pathogens

  • Successfully manufacturing a hyperimmune against Covid-19 for clinical trial

  • Successfully completing the sentinel group of the clinical trial of the hyperimmune against Covid-19

Company Overview

  • Transforming the lives of patients

    With a safe, secure, sustainable supply of therapeutic plasma products

  • The Aegros HaemaFrac® will save lives and improve people’s health globally

    This is a breakthrough the world has been waiting for

Aegros Ltd is a developer of therapeutic plasma drugs, dedicated to creating hyperimmunes for both existing and emerging diseases. With a focus on the therapeutic plasma products market, the company utilizes cutting-edge technology that leverages the mobility of ions in an electric field to transport proteins across a membrane into a collection chamber.

This innovative approach enables Aegros to develop hyperimmune products for a wide range of diseases and illnesses, empowering frontline healthcare workers in combating these conditions and providing passive immunity globally. The company aims to integrate its multi-patent pending CyMES technology with existing processes to deliver safer and more affordable therapeutic plasma products.

At Aegros, they firmly believe that access to life-saving drugs is a fundamental human right, not a privilege. Ultimately, their mission is centred around putting patients first through innovation.


Aegros represents a game-changing platform that is revolutionizing the healthcare industry.

With its streamlined processes, integrated EHR system, patient engagement tools, and robust data security measures, Aegros empowers healthcare providers to deliver high-quality care while fostering a patient-centric approach.

Products & Services


Aegros’s HaemaFrac® is a groundbreaking membrane-based tangential flow preparative electrophoresis process that revolutionizes plasma fractionation technologies. Unlike traditional ethanol-based methods, HaemaFrac® offers a single-step, scalable solution that achieves higher yield, purity, and process efficiency while eliminating the need for multiple steps and solvents. This innovative technology enables the isolation of plasma proteins in their native state and the simultaneous removal of viruses, representing a significant advancement for the industry.

With the blood and plasma industry dominated by long-standing technologies from CSL, Grifols, and Takeda, Aegros aims to disrupt the market with the HaemaFrac® machine and process. Aegros’ solution not only achieves higher yields from smaller batch sizes but also operates significantly faster, leading to reduced COGS. This increased efficiency enables countries to establish domestic fractionation industries, enhancing self-sufficiency.


Aegros is developing Covimmune™, a hyperimmune against Covid-19, as our first product.

Extensive research and clinical trials are being undertaken because it is vital that this new treatment option against Covid-19 takes its place among the medicines that have already been developed.

Additional Information

  • Financials


  • Management
  • Professor Hari Nair

    Founding Executive Chair

  • John Manusu

    Founding Managing Director

  • Janet Bowen

    Executive Board Director Quality & Regulatory

  • Damian Thornton

    CEO of Aegros Engineering & Interim CEO Aegros Therapeutics

  • Alexander Stuke

    Chief Strategy Officer

  • Leighton Hopper

    CEO Aegros Consumables



  • July 2023

    Promoting and Protecting Future Science and Scientists
    Read more
  • May 2023

    Primary Immunity Week was a Chance to Learn
    Read more
  • May 2023

    HF-02: The next evolution of HaemaFrac®
    Read more
  • April 2023

    Aegros Agreement Ensures BioPark Australia
    Read more
  • March 2023

    Aegros & Invested In Queensland – Benefits All Of Us
    Read more

Ask us a question

Ask Us a Question

Already a member?

Login now

Become a member

Register now

    Thank you for your enquiry.
    We will be in touch as soon as possible.